GGrantIndex
Sort

65,743 grants matching single cell sequencing

IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease

$588,085
Thomas A. Platts-Mills · University Of Virginia · R37 · FY2018 · AI

Defining human skin immunity to cutaneous leishmaniasis via systems immunology approaches

$588,055
Joshua Lacsina · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

Reduction of Brain AVM Severity through Inhibition of Pathogenic Angiogenesis

$588,018
Hua Su · University Of California, San Francisco · R01 · FY2020 · NS

Dissect regulation of glial nets surrounding amyloid plaques in Alzheimer's disease

$588,010
Roland Horst Friedel · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AG

Single-cell proteomic identification of novel markers of senescence

$588,001
Zhixun Dou · Massachusetts General Hospital · UG3 · FY2022 · CA

Single-cell proteomic identification of novel markers of senescence

$588,000
Zhixun Dou · Massachusetts General Hospital · UG3 · FY2021 · CA

Molecular Analysis of Nuclear Pore Complex Function

$587,929
Susan R. Wente · Vanderbilt University · R37 · FY2017 · GM

Molecular Analysis of Nuclear Pore Complex Function

$587,929
Susan R. Wente · Vanderbilt University · R37 · FY2016 · GM

Molecular Analysis of Nuclear Pore Complex Function

$587,929
Susan R. Wente · Vanderbilt University · R37 · FY2015 · GM

Molecular Analysis of Nuclear Pore Complex Function

$587,929
Susan R. Wente · Vanderbilt University · R37 · FY2019 · GM

Heparan sulfate proteoglycan in the brain vascular clearance of amyloid-β and Alzheimer's disease

$587,928
Lianchun Wang · University Of South Florida · R01 · FY2025 · AG

Identifying Brain Epitranscriptomic Changes Associated with Alcohol Use Disorder

$587,928
Huiping Zhang · Boston University Medical Campus · R01 · FY2022 · AA

Dissecting dynamic genetic effects from thymus development to immune-mediated disease

$587,919
Hannah Verena Meyer · Cold Spring Harbor Laboratory · R01 · FY2022 · AI

Molecular Pathways of Pain Generation in Osteoarthritis

$587,842
Anne-Marie Malfait · Rush University Medical Center · R01 · FY2022 · AR

Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors

$587,827
Julie Zikherman · University Of California, San Francisco · R01 · FY2025 · AI

Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors

$587,774
Julie Zikherman · University Of California, San Francisco · R01 · FY2024 · AI

Experimental Studies of Endoscopic Third Ventriculostomy and Choroid Plexus Cauterization in Hydrocephalus

$587,728
James Patterson McAllister · Virginia Commonwealth University · R01 · FY2024 · NS

Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis

$587,726
William H Robinson · Stanford University · R01 · FY2023 · AI

Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors

$587,719
Julie Zikherman · University Of California, San Francisco · R01 · FY2023 · AI

National Gnotobiotic Rodent Resource Center

$587,706
Ryan Balfour Sartor · Univ Of North Carolina Chapel Hill · P40 · FY2019 · OD

An integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skin

$587,690
Ashani T Weeraratna · Johns Hopkins University · R01 · FY2020 · CA

A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer

$587,662
Peter J Houghton · University Of Texas Hlth Science Center · U01 · FY2022 · CA

PKR sensing of mitochondrial dsRNA in childhood Sjogrens disease

$587,654
Seunghee Cha · University Of Florida · R01 · FY2025 · DE

Non-invasive imaging of the anti-tumor immune response

$587,640
Novalia Pishesha · Boston Children'S Hospital · R01 · FY2025 · CA

Models, mechanisms and treatment of LMX1B-induced glaucoma

$587,611
Simon W John · Columbia University Health Sciences · R01 · FY2021 · EY